Berbamine Inhibits the Biological Activities of Prostate Cancer Cells by Modulating the ROS/NF-κB Axis


Cite item

Full Text

Abstract

Background/Introduction:Prostate cancer ranks as the second leading cause of cancer death. No effective pharmacological agent is available for prostate cancer treatment. Berbamine is an alkaloid extracted from the Chinese herb berberis, which exerts an effect on inhibiting cancer cell proliferation.

Objective: This study aimed to explore the mechanism of berbamine in inhibiting prostate cancer.

Methods: Prostate cancer cell lines PC-3 and DU145 cells were used to evaluate the effects of berbamine. Cell viability was determined using cell-counting kit 8. The intracellular reactive oxygen species (ROS) levels were measured using a ROS assay kit. Cell apoptosis rate was examined using flow cytometry. The protein levels associated with cell proliferation, NF-κB pathway, and apoptosis were determined using western blot.

Results: It was found that berbamine induced cell cycle arrest in the S phase and inhibited prostate cancer cell growth and proliferation. Berbamine inhibited prostate cancer cells by inhibiting the activation of the NF-κB pathway in vitro. Berbamine increased ROS as an upstream molecule that inhibited the NF-κB pathway.

Conclusion: Our results demonstrated that berbamine can effectively reduce the proliferation of prostate cancer cells. The ROS/NF-κB axis plays a crucial role in berbamine-mediated anti-prostate cancer cell proliferation.

About the authors

Wanli Zhao

Department of Urology,, the Third Hospital of Hebei Medical University

Email: info@benthamscience.net

Yuqing Jiang

Department of Urology, Third Hospital of Hebei Medical University

Email: info@benthamscience.net

Xiaopeng Jia

Department of Urology,, the Third Hospital of Hebei Medical University

Email: info@benthamscience.net

Xiuli Wang

Department of Anesthesiology, The Third Hospital of Hebei Medical University

Email: info@benthamscience.net

Yuexian Guo

Department of Urology,, the Third Hospital of Hebei Medical University,

Author for correspondence.
Email: info@benthamscience.net

References

  1. Gandaglia, G.; Leni, R.; Bray, F.; Fleshner, N.; Freedland, S.J.; Kibel, A.; Stattin, P.; Van Poppel, H.; La Vecchia, C. Epidemiology and prevention of prostate cancer. Eur. Urol. Oncol., 2021, 4(6), 877-892. doi: 10.1016/j.euo.2021.09.006 PMID: 34716119
  2. Giona, S. The Epidemiology of Prostate Cancer. In: Prostate Cancer, Bott, S. R. J.; Ng, K. L., Eds. Exon publications: Brisbane (AU), 2021.
  3. Michaelson, M.D.; Cotter, S.E.; Gargollo, P.C.; Zietman, A.L.; Dahl, D.M.; Smith, M.R. Management of complications of prostate cancer treatment. CA Cancer J. Clin., 2008, 58(4), 196-213. doi: 10.3322/CA.2008.0002 PMID: 18502900
  4. Trewartha, D.; Carter, K. Advances in prostate cancer treatment. Nat. Rev. Drug Discov., 2013, 12(11), 823-824. doi: 10.1038/nrd4068 PMID: 24172327
  5. Farooqi, A.A.; Wen, R.; Attar, R.; Taverna, S.; Butt, G.; Xu, B. Regulation of cell-signaling pathways by berbamine in different cancers. Int. J. Mol. Sci., 2022, 23(5), 2758. doi: 10.3390/ijms23052758 PMID: 35269900
  6. Duan, H.; Luan, J.; Liu, Q.; Yagasaki, K.; Zhang, G. Suppression of human lung cancer cell growth and migration by berbamine. Cytotechnology, 2010, 62(4), 341-348. doi: 10.1007/s10616-009-9240-x PMID: 19967402
  7. Zhao, X.; He, Z.; Wu, D.; Xu, R. Berbamine selectively induces apoptosis of human acute promyelocytic leukemia cells via survivin-mediated pathway. Chin. Med. J., 2007, 120(9), 802-806. doi: 10.1097/00029330-200705010-00012 PMID: 17531122
  8. Zhao, Y.; Tan, Y.; Wu, G.; Liu, L.; Wang, Y.; Luo, Y.; Shi, J.; Huang, H. Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia. Int. J. Hematol., 2011, 94(2), 156-162. doi: 10.1007/s12185-011-0887-7 PMID: 21728004
  9. Nam, S.; Xie, J.; Perkins, A.; Ma, Y.; Yang, F.; Wu, J.; Wang, Y.; Xu, R.; Huang, W.; Horne, D.A.; Jove, R. Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells. Mol. Oncol., 2012, 6(5), 484-493. doi: 10.1016/j.molonc.2012.05.002 PMID: 22717603
  10. Meng, Z.; Li, T.; Ma, X.; Wang, X.; Van Ness, C.; Gan, Y.; Zhou, H.; Tang, J.; Lou, G.; Wang, Y.; Wu, J.; Yen, Y.; Xu, R.; Huang, W. Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca2/calmodulin-dependent protein kinase II. Mol. Cancer Ther., 2013, 12(10), 2067-2077. doi: 10.1158/1535-7163.MCT-13-0314 PMID: 23960096
  11. Wang, S.; Liu, Q.; Zhang, Y.; Liu, K.; Yu, P.; Liu, K.; Luan, J.; Duan, H.; Lu, Z.; Wang, F.; Wu, E.; Yagasaki, K.; Zhang, G. Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action. Mol. Cancer, 2009, 8(1), 81. doi: 10.1186/1476-4598-8-81 PMID: 19796390
  12. Zhang, H.; Jiao, Y.; Shi, C.; Song, X.; Chang, Y.; Ren, Y.; Shi, X. Berbamine suppresses cell viability and induces apoptosis in colorectal cancer via activating p53-dependent apoptotic signaling pathway. Cytotechnology, 2018, 70(1), 321-329. doi: 10.1007/s10616-017-0146-8 PMID: 28965196
  13. D'Autréaux, B.; Toledano, M.B. ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol., 2007, 8(10), 813-824. doi: 10.1038/nrm2256 PMID: 17848967
  14. Ingham, M.; Schwartz, G.K. Cell-cycle therapeutics come of age. J. Clin. Oncol., 2017, 35(25), 2949-2959. doi: 10.1200/JCO.2016.69.0032 PMID: 28580868
  15. McLaughlin, F.; Finn, P.; La Thangue, N.B. The cell cycle, chromatin and cancer: Mechanism-based therapeutics come of age. Drug Discov. Today, 2003, 8(17), 793-802. doi: 10.1016/S1359-6446(03)02792-2 PMID: 12946642
  16. Stein, S.J. Baldwin, A.S. NF-κB suppresses ROS levels in BCR-ABL+ cells to prevent activation of JNK and cell death. Oncogene, 2011, 30(45), 4557-4566. doi: 10.1038/onc.2011.156 PMID: 21625221
  17. Liu, J.Y.; Zeng, Q.H.; Cao, P.G.; Xie, D.; Chen, X.; Yang, F.; He, L.Y.; Dai, Y.B.; Li, J.J.; Liu, X.M.; Zeng, H.L.; Zhu, Y.X.; Gong, L.; Cheng, Y.; Zhou, J.D.; Hu, J.; Bo, H.; Xu, Z.Z.; Cao, K. RIPK4 promotes bladder urothelial carcinoma cell aggressiveness by upregulating VEGF-A through the NF-κB pathway. Br. J. Cancer, 2018, 118(12), 1617-1627. doi: 10.1038/s41416-018-0116-8 PMID: 29867225
  18. Wei, Y.L.; Liang, Y.; Xu, L.; Zhao, X.Y. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway. Anat. Rec., 2009, 292(7), 945-950. doi: 10.1002/ar.20924 PMID: 19548306
  19. Liang, Y.; Xu, R.; Zhang, L.; Zhao, X. Berbamine, a novel nuclear factor κB inhibitor, inhibits growth and induces apoptosis in human myeloma cells. Acta Pharmacol. Sin., 2009, 30(12), 1659-1665. doi: 10.1038/aps.2009.167 PMID: 19960011
  20. Liang, Y.; He, X.; Li, X.; Zhang, X.; Zhang, X.; Zhang, L.; Qiu, X.; Zhao, X.; Xu, R. 4-Chlorbenzoyl berbamine, a novel derivative of the natural product berbamine, potently inhibits the growth of human myeloma cells by modulating the NF-κB and JNK signalling pathways. Cancer Invest., 2016, 34(10), 496-505. doi: 10.1080/07357907.2016.1235709 PMID: 27768381
  21. Kleih, M.; Böpple, K.; Dong, M.; Gaißler, A.; Heine, S.; Olayioye, M.A.; Aulitzky, W.E.; Essmann, F. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death Dis., 2019, 10(11), 851. doi: 10.1038/s41419-019-2081-4 PMID: 31699970
  22. Reshetnikov, V.; Daum, S.; Janko, C.; Karawacka, W.; Tietze, R.; Alexiou, C.; Paryzhak, S.; Dumych, T.; Bilyy, R.; Tripal, P.; Schmid, B.; Palmisano, R.; Mokhir, A. ROS-Responsive N-Alkylaminoferrocenes for cancer-cell-specific targeting of mitochondria. Angew. Chem. Int. Ed., 2018, 57(37), 11943-11946. doi: 10.1002/anie.201805955 PMID: 30035345
  23. Zeng, L.; Li, Y.; Li, T.; Cao, W.; Yi, Y.; Geng, W.; Sun, Z.; Xu, H. Selenium-platinum coordination compounds as novel anticancer drugs: selectively killing cancer cells via a reactive oxygen species (ROS)-mediated apoptosis route. Chem. Asian J., 2014, 9(8), 2295-2302. doi: 10.1002/asia.201402256 PMID: 24844800
  24. Kirkwood, N.K.; O'Reilly, M.; Derudas, M.; Kenyon, E.J.; Huckvale, R.; van Netten, S.M.; Ward, S.E.; Richardson, G.P.; Kros, C.J. d-tubocurarine and berbamine: Alkaloids that are permeant blockers of the hair cell's mechano-electrical transducer channel and protect from aminoglycoside toxicity. Front. Cell. Neurosci., 2017, 11, 262. doi: 10.3389/fncel.2017.00262 PMID: 28928635
  25. He, Z.W.; Zhao, X.Y.; Xu, R.Z.; Wu, D. Effects of berbamine on growth of leukemia cell line NB4 and its mechanism. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2006, 35(2), 209-214. PMID: 16610091
  26. Wei, Y.L.; Xu, L.; Zhao, X.Y. Mechanism related to inhibition of leukemia K562 cells by berbamine. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2009, 38(4), 387-391. PMID: 19693977
  27. Yu, B.; Liu, L.; Yan, J.; Cao, J.; Cao, Y. Effect of berbamine on invasion and metastasis of human liver cancer SMMC-7721 cells and its possible mechanism. Anticancer Drugs, 2022, 33(1), e178-e185. doi: 10.1097/CAD.0000000000001179 PMID: 34321418
  28. Zhang, C.M.; Gao, L.; Zheng, Y.J.; Yang, H.T. Berbamine increases myocardial contractility via a Ca2+-independent mechanism. J. Cardiovasc. Pharmacol., 2011, 58(1), 40-48. doi: 10.1097/FJC.0b013e31821b70d1 PMID: 21753257
  29. Liu, L.; Xu, Z.; Yu, B.; Tao, L.; Cao, Y. Berbamine inhibits cell proliferation and migration and induces cell death of lung cancer cells via regulating c-Maf, PI3K/Akt, and MDM2-P53 pathways. Evid. Based Complement. Alternat. Med., 2021, 2021, 1-20. doi: 10.1155/2021/5517143 PMID: 34306137
  30. Wang, G.Y.; Lv, Q.H.; Dong, Q.; Xu, R.Z.; Dong, Q.H. Berbamine induces Fas-mediated apoptosis in human hepatocellular carcinoma HepG2 cells and inhibits its tumor growth in nude mice. J. Asian Nat. Prod. Res., 2009, 11(3), 219-228. doi: 10.1080/10286020802675076 PMID: 19408145
  31. Wang, Z.; Guo, H.Y.; Huang, Y.L. Escopoletin treatment induces apoptosis and arrests cell cycle at G0/G1 phase in the oral squamous cancer cell lines. Int. J. Clin. Exp. Med., 2015, 8(7), 11496-11501. PMID: 26379969
  32. Yamamoto, T.; Nishita, T.; Taga, A. Dark colored maple syrup treatment induces S phase cell cycle arrest via reduced proliferating cell nuclear antigen expression in colorectal cancer cells. Oncol. Lett., 2019, 17(3), 2713-2720. doi: 10.3892/ol.2019.9928 PMID: 30854045
  33. Izzo, J.G.; Wu, X.; Wu, T.T.; Huang, P.; Lee, J.S.; Liao, Z.; Lee, J.H.; Bhutani, M.S.; Hofstetter, W.; Maru, D.; Hung, M.C.; Ajani, J.A. Therapy-induced expression of NF-κB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis. Esophagus, 2009, 22(2), 127-132. doi: 10.1111/j.1442-2050.2008.00884.x PMID: 19021681
  34. Kuo, S.H.; Yang, S.H.; Wei, M.F.; Lee, H.W.; Tien, Y.W.; Cheng, A.L.; Yeh, K.H. Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling. Cancer Cell Int., 2021, 21(1), 436. doi: 10.1186/s12935-021-02143-z PMID: 34412631
  35. Lin, G.; Zheng, X.; Li, C.; Chen, Q.; Ye, Y. KRAS mutation and NF-κB activation indicates tolerance of chemotherapy and poor prognosis in colorectal cancer. Dig. Dis. Sci., 2012, 57(9), 2325-2333. doi: 10.1007/s10620-012-2172-x PMID: 22526587
  36. Lee, S.H.; Son, S.M.; Son, D.J.; Kim, S.M.; Kim, T.J.; Song, S.; Moon, D.C.; Lee, H.W.; Ryu, J.C.; Yoon, D.Y.; Hong, J.T. Epothilones induce human colon cancer SW620 cell apoptosis via the tubulin polymerization-independent activation of the nuclear factor-κB/IκB kinase signal pathway. Mol. Cancer Ther., 2007, 6(10), 2786-2797. doi: 10.1158/1535-7163.MCT-07-0002 PMID: 17938270
  37. Péant, B.; Diallo, J.S.; Dufour, F.; Le Page, C.; Delvoye, N.; Saad, F.; Mes-Masson, A.M. Over-expression of IκB-kinase-ε (IKKε/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines. Prostate, 2009, 69(7), 706-718. doi: 10.1002/pros.20912 PMID: 19170126
  38. Parrondo, R. Pozas, A.; Reiner, T.; Rai, P.; Perez-Stable, C. NF-κB activation enhances cell death by antimitotic drugs in human prostate cancer cells. Mol. Cancer, 2010, 9(1), 182. doi: 10.1186/1476-4598-9-182 PMID: 20618955
  39. Yu, J.; Jin, J.; Li, Y. The physiological functions of IKK-selective substrate identification and their critical roles in diseases. STEMedicine, 2020, 1(4)e49 doi: 10.37175/stemedicine.v1i4.49
  40. Liu, L.; Yin, S.; Brobbey, C.; Gan, W. Ubiquitination in cancer stem cell: Roles and targeted cancer therapy. STEMedicine, 2020, 1(3)e37 doi: 10.37175/stemedicine.v1i3.37
  41. Misra, U.K.; Deedwania, R.; Pizzo, S.V. Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78. J. Biol. Chem., 2006, 281(19), 13694-13707. doi: 10.1074/jbc.M511694200 PMID: 16543232
  42. Zhao, Y.; Lv, J.J.; Chen, J.; Jin, X.B.; Wang, M.W.; Su, Z.H.; Wang, L.Y.; Zhang, H.Y. Berbamine inhibited the growth of prostate cancer cells in vivo and in vitro via triggering intrinsic pathway of apoptosis. Prostate Cancer Prostatic Dis., 2016, 19(4), 358-366. doi: 10.1038/pcan.2016.29 PMID: 27431500
  43. Kang, S.W.; Lee, S.; Lee, E.K. ROS and energy metabolism in cancer cells: Alliance for fast growth. Arch. Pharm. Res., 2015, 38(3), 338-345. doi: 10.1007/s12272-015-0550-6 PMID: 25599615
  44. Al-Oqail, M.M. Anticancer efficacies of Krameria lappacea extracts against human breast cancer cell line (MCF-7): Role of oxidative stress and ROS generation. Saudi Pharm. J., 2021, 29(3), 244-251. doi: 10.1016/j.jsps.2021.01.008 PMID: 33981173
  45. Qiao, L.; Liu, J.; Kuang, S.; Liao, X.; Kou, J.; Ji, L.; Chao, H. A mitochondrion-targeted BODIPY-Ir(III) conjugate as a photoinduced ROS generator for the oxidative destruction of triple-negative breast cancer cells. Dalton Trans., 2021, 50(40), 14332-14341. doi: 10.1039/D1DT01460A PMID: 34558567
  46. Ulker, O.C.; Panieri, E.; Suzen, S.; Jaganjac, M.; Zarkovic, N.; Saso, L. Short overview on the relevance of microRNA-reactive oxygen species (ROS) interactions and lipid peroxidation for modulation of oxidative stress-mediated signalling pathways in cancer treatment. J. Pharm. Pharmacol., 2022, 74(4), 503-515. PMID: 33769543

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Bentham Science Publishers